Skip to main navigation Skip to search Skip to main content

Price determinants and pricing policies concerning potentially innovative health technologies: a scoping review

  • Nicolas S. H. Xander*
  • , Tom Belleman
  • , Maximilian Salcher-Konrad
  • , Anne Hendrickx
  • , Jeffrey Chen
  • , Anne-Sophie Klein Gebbink
  • , Peter Schneider
  • , Kate Morgan
  • , Oliver Groene
  • , Isabelle Durand-Zaleski
  • , Frederick W. Thielen
  • , Carin A. Uyl-de Groot
  • *Corresponding author for this work
  • Erasmus School of Health Policy & Management
  • Erasmus University Rotterdam
  • Gesundheit Österreich GmbH
  • The London School of Economics and Political Science
  • International Association of Mutual Benefit Societies (AIM)
  • Hospital of Zala County
  • OptiMedis AG
  • Witten/Herdecke University
  • Assistance publique – Hôpitaux de Paris
  • Université Paris-Est Créteil Val de Marne

Research output: Contribution to journalArticleAcademicpeer-review

26 Downloads (Pure)

Abstract

Background: Policymakers face challenges in developing pricing policies for potentially innovative healthcare technologies (pIHTs) that balance limited budgets, access, and incentives for innovation. This study aimed to map existing evidence and identify knowledge gaps regarding price determinants and pricing policies for pIHTs and their effect on access and sustainability. Methods: We conducted a scoping Review of scientific and grey literature in English published between 2014 and September 2023 with pre-specified inclusion and exclusion criteria to identify stakeholder-informed price determinants, pricing policies applied by European Economic Area (EEA) or Organisation for Economic Cooperation and Development (OECD) member states, and their access-related impacts. Literature databases and various stakeholder organisation websites were searched. Further records were included through snowballing and manual addition. Results: 135 Records were included. Stakeholder views on price determinants were available from 15 records and predominantly involved value-based determinants. Pricing policies in EEA/OECD member states are heterogeneous and often feature a mix of policy interventions and implementation methods. External price referencing (EPR), while yielding short-term affordability improvements, is associated with price inequities and launch strategies impairing patient access. Policies combining pricing methods and considering a pIHT’s value have more positive access-related impact but may face feasibility and implementation challenges. Two records mentioned medical device pricing; none featured environmental aspects. Conclusion: While EPR is commonly applied across Europe, value-informed pricing in connection with health technology assessment is more favoured regarding pIHT access in the literature. Knowledge gaps concern medical device pricing, stakeholder views on price determinants, and the implementation of environmental aspects in pIHT pricing.
Original languageEnglish
JournalEuropean journal of health economics : HEPAC
Early online date2025
DOIs
Publication statusE-pub ahead of print - 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 12 - Responsible Consumption and Production
    SDG 12 Responsible Consumption and Production
  2. SDG 17 - Partnerships for the Goals
    SDG 17 Partnerships for the Goals

Keywords

  • Innovation
  • Patient access
  • Pharmaceutical pricing
  • Price determinants
  • Pricing policies

Fingerprint

Dive into the research topics of 'Price determinants and pricing policies concerning potentially innovative health technologies: a scoping review'. Together they form a unique fingerprint.

Cite this